UNSPSC 51332851: Fluphenazine enanthate

This classification denotes an antipsychotic agent with the molecular formula C29H38F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QSB34YF0W9, chemically known as sq 16,114 but more generally known as fluphenazine enantate, which bears US NIH Compound Identifier 3389. European Medicines Agency schedules Fluphenazine enantate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02231MIG. Most nations, for tariff and trade purposes, schedule fluphenazine enanthate under HS 29343090.

As of Q4 2014, FLUPHENAZINE ENANTHATE remains US FDA's Preferred Term for this commodity. Fluphenazine enanthate bears US NLM identifiers UMLS ID C0066682 and NCI Concept Code C65726. SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.

UNSPSC 51332851 Fluphenazine enanthate is a Commodity code for a specific injectable antipsychotic medication, but the recent state and local procurement activity tagged under this code does not reflect purchases of fluphenazine enanthate itself. Instead, the single recent opportunity on record shows Seminole County, Florida soliciting naloxone and drug deactivation systems—products unrelated to the code's nominal scope. This mismatch suggests the code carries little relevant recent activity for firms pursuing antipsychotic pharmaceutical contracts at the state and local level, or that the tagging reflects a data classification error rather than genuine demand for fluphenazine enanthate.

Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The bid deadline was July 26, 2023 (a historical date that appears inconsistent with the June 2026 posting). The procurement requires vendors to include all shipping and delivery costs in their proposals, maintain workers' compensation and commercial general liability insurance, comply with E-Verify, and certify drug-free workplace status; it includes a two-year initial term with one-year renewal option and a three-month probationary period. No explicit disadvantaged-enterprise set-asides are noted. This single opportunity does not establish meaningful geographic spread or a pattern of state and local demand under this code.